DE602005015415D1 - N ausgewählter n-3-fettsäuren zur behandlung von erkrankungen des zentralen nervensystems - Google Patents

N ausgewählter n-3-fettsäuren zur behandlung von erkrankungen des zentralen nervensystems

Info

Publication number
DE602005015415D1
DE602005015415D1 DE602005015415T DE602005015415T DE602005015415D1 DE 602005015415 D1 DE602005015415 D1 DE 602005015415D1 DE 602005015415 T DE602005015415 T DE 602005015415T DE 602005015415 T DE602005015415 T DE 602005015415T DE 602005015415 D1 DE602005015415 D1 DE 602005015415D1
Authority
DE
Germany
Prior art keywords
diseases
treatment
fatty acids
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005015415T
Other languages
English (en)
Inventor
Tiberio Bruzzese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34803698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005015415(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of DE602005015415D1 publication Critical patent/DE602005015415D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005015415T 2004-01-21 2005-01-20 N ausgewählter n-3-fettsäuren zur behandlung von erkrankungen des zentralen nervensystems Active DE602005015415D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000069A ITMI20040069A1 (it) 2004-01-21 2004-01-21 Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
PCT/EP2005/000522 WO2005070411A1 (en) 2004-01-21 2005-01-20 USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES

Publications (1)

Publication Number Publication Date
DE602005015415D1 true DE602005015415D1 (de) 2009-08-27

Family

ID=34803698

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005015415T Active DE602005015415D1 (de) 2004-01-21 2005-01-20 N ausgewählter n-3-fettsäuren zur behandlung von erkrankungen des zentralen nervensystems

Country Status (12)

Country Link
US (1) US8829048B2 (de)
EP (1) EP1706106B9 (de)
JP (1) JP5087280B2 (de)
DE (1) DE602005015415D1 (de)
DK (1) DK1706106T3 (de)
ES (1) ES2329809T3 (de)
HR (1) HRP20090550T1 (de)
IT (1) ITMI20040069A1 (de)
PL (1) PL1706106T3 (de)
PT (1) PT1706106E (de)
RS (1) RS51195B (de)
WO (1) WO2005070411A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1772146A1 (de) * 2005-10-03 2007-04-11 Neuropharma, S.A. Merfach ungesättigte Fettsäuren als BACE-Inhibitoren
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
NZ569676A (en) 2005-12-21 2012-03-30 Brudy Technology S L Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
ES2415684T3 (es) 2007-03-28 2013-07-26 Aker Biomarine As Composiciones de aceite de kril biológicamente eficaces
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US20110166229A1 (en) 2008-09-09 2011-07-07 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
RU2718983C2 (ru) 2015-02-11 2020-04-15 Акер Биомарин Антарктик Ас Композиции липидов
EP3256003B1 (de) 2015-02-11 2022-11-09 Aker Biomarine Antarctic AS Lipidextraktionsverfahren
EP3586640A1 (de) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha-angereicherte mehrfach ungesättigte fettsäurezusammensetzungen
PL238670B1 (pl) * 2018-07-06 2021-09-20 Skotan Spolka Akcyjna Sposób otrzymywania oczyszczonej kompozycji estrów kwasów tłuszczowych i kompozycja estrów kwasów tłuszczowych
WO2022050355A1 (ja) * 2020-09-04 2022-03-10 国立大学法人千葉大学 ドコサヘキサエン酸、ドコサヘキサエノイル基含有ホスファチジン酸、又はその誘導体によるセロトニントランスポーター関連精神疾患の予防・治療剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
DE3739700A1 (de) * 1987-11-24 1989-06-08 Guenther Dr Med Jeschke Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin
JP2524217B2 (ja) 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB2218904A (en) 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2688145B1 (fr) 1992-03-06 1994-09-23 Borden France Sa Procede et installation pour separer un effluent sous forme de vapeur d'un courant de gaz vecteur.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
NZ334852A (en) * 1996-10-11 2001-05-25 Scotia Holdings Plc Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
IT1320180B1 (it) * 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Also Published As

Publication number Publication date
ES2329809T3 (es) 2009-12-01
PT1706106E (pt) 2009-09-04
ITMI20040069A1 (it) 2004-04-21
PL1706106T3 (pl) 2009-12-31
EP1706106B9 (de) 2009-09-16
EP1706106B1 (de) 2009-07-15
DK1706106T3 (da) 2009-10-12
EP1706106A1 (de) 2006-10-04
RS51195B (sr) 2010-10-31
JP2007518764A (ja) 2007-07-12
HRP20090550T1 (hr) 2010-01-31
US8829048B2 (en) 2014-09-09
US20070161705A1 (en) 2007-07-12
JP5087280B2 (ja) 2012-12-05
WO2005070411A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
DE602005015415D1 (de) N ausgewählter n-3-fettsäuren zur behandlung von erkrankungen des zentralen nervensystems
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602006006354D1 (de) Pinolensäure zur Behandlung von Übergewicht
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE369133T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE503752T1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
DE602005017605D1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen

Legal Events

Date Code Title Description
8363 Opposition against the patent